Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial

Clin Neuropharmacol. 2007 Sep-Oct;30(5):276-80. doi: 10.1097/wnf.0b013e318050c9f9.

Abstract

Eleven postmenopausal women with Parkinson disease and levodopa-induced peak-dose dyskinesias underwent a double-blind, placebo-controlled, crossover study. The active treatment consisted of estrogen replacement therapy for 12 weeks, followed by medroxyprogesterone acetate for 2 weeks. Estrogen replacement therapy-medroxyprogesterone acetate administration significantly improved peak-dose dyskinesia without worsening motor disability, thus suggesting a possible benefit on dyskinesias in postmenopausal women with Parkinson disease.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Akathisia, Drug-Induced / drug therapy*
  • Akathisia, Drug-Induced / etiology
  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Antiparkinson Agents / adverse effects*
  • Cross-Over Studies
  • Double-Blind Method
  • Estrogens / administration & dosage*
  • Female
  • Humans
  • Levodopa / adverse effects
  • Medroxyprogesterone Acetate / administration & dosage*
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Postmenopause
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Antiparkinson Agents
  • Estrogens
  • Levodopa
  • Medroxyprogesterone Acetate